

Myanmar

Support for Vaccine: DTP-HepB-Hib This Decision Letter sets out the Programme Terms of a Programme.

| | | | | | | | |
|--|---|---------------------|----------------------|-------------|------|------|--------------------|
| 1. Country: | Myanmar | | | | | | |
| 2. Vaccine grant number: | 12-MMR-08b-Y, 1216-MMR-04C-X, 1721-MMR-04c-X | | | | | | |
| 3. Date of Decision Letter: | 30 September 2019 | | | | | | |
| 4. Date of the Partnership Framework Agreement: | 4 April 2014 | | | | | | |
| 5. Programme title: | New Vaccine Support (NVS), DTP-HepB-Hib, Routine | | | | | | |
| 6. Vaccine type: | DTP-HepB-Hib | | | | | | |
| 7. Requested product presentation and formulation of vaccine: | Penta, 10 dose(s) per vial, LIQUID | | | | | | |
| 8. Programme Duration:¹ | 2002-2021 | | | | | | |
| 9. Programme Budget (indicative):² | (subject to the terms of the Partnership Framework Agreement) | | | | | | |
| | 2002-2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Total ² |
| Programme Budget (US\$) | 46,467,594 | 1,760,500 | 2,152,500 | - | - | - | 50,380,594 |
| 10. Vaccine introduction grant | | | | | | | |
| | Approval | | | | | | |
| | Year | Grant Number | Amount (US\$) | | | | |
| | 2002 | n/a | 100,000 | | | | |
| | 2012 | 12-MMR-08b-Y | 1,209,000 | | | | |
| | Disbursement | | | | | | |
| | Disbursement date | | Amount (US\$) | | | | |
| | 31 December, 2005 | | 100,000 | | | | |
| | 05 November, 2012 | | 1,209,000 | | | | |
| 11. Product switch grant | Not applicable | | | | | | |
| 12. Indicative Annual Amounts:³ | (subject to the terms of the Partnership Framework Agreement) | | | | | | |
| | Type of supplies to be purchased with Gavi funds | 2002-2019 | 2020 | 2021 | | | |

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

| | | | |
|-------------------------|------------|-----------|---|
| Number of vaccine doses | | 2,437,900 | - |
| Annual Amounts (US\$) | 46,467,594 | 1,760,500 | - |

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

| Type of supplies to be purchased with Country funds in each year | 2020 | 2021 | 2022 | 2023 | 2024 |
|--|---------|---------|------|------|------|
| Number of vaccine doses | 282,500 | 403,500 | - | - | - |
| Number of AD syringes | 248,200 | 355,100 | - | - | - |
| Number of re-constitution syringes | - | - | - | - | - |
| Number of safety boxes | 2,750 | 3,925 | - | - | - |
| Value of vaccine doses (US\$) | 197,410 | 282,442 | - | - | - |
| Total co-financing payments (US\$) (including freight) | 215,000 | 307,500 | - | - | - |

16. Operational support for campaigns:
Not applicable

17. Additional Reporting Requirements:

| | Due dates |
|--|-------------------------------------|
| To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. | 31 March 2020 15 May 2020 N/A |
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Gavi Secretariat |

18. Financial clarifications:

Country shall provide the following clarifications to Gavi*:

Not applicable

* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.

19. Other conditions:

Not applicable

Signed by,

On behalf of Gavi



Thabani Maphosa
Managing Director, Country Programmes
30 September 2019